Company / Named in our posts
Elicio Therapeutics, Inc..
Follow Elicio Therapeutics, Inc.A clinical-stage biopharmaceutical company advancing Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.[1]
01Deal
Deals on Carrywatch
Every deal that names Elicio Therapeutics, Inc., and its role in each.
Angion Biomedica Corp. / Elicio Therapeutics, Inc.
Angion Biomedica and Elicio complete merger transaction
See deal detailsDeal Web
Elicio Therapeutics, Inc. and 0 firms it shares a posted deal with, and the path to any other firm.
Financials
5 fiscal years of figures as Elicio Therapeutics, Inc. reported them.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01Current Report on Form 8-K
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming Elicio Therapeutics, Inc.:
- P01